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Background: Chronic Lyme disease is a term that describes a constellation of persistent symptoms in patients with
or without evidence of previous Borrelia burgdorferi infection. Patients labeled as having chronic Lyme disease have
a substantial clinical burden. Little is known about chronic Lyme disease patient experiences in the healthcare
system and their relationships with healthcare providers. The purpose of this study was to gather insights about the
experiences of patients who carry a diagnosis of chronic Lyme disease in the United States healthcare system.
Methods: Qualitative, phenomenological study in 12 adult participants who identified themselves as having
chronic Lyme disease. Semi-structured face-to-face in-depth interviews were conducted, 60–90 minutes in length,
focusing on perceptions of disease burden and of their healthcare providers, using the dimensions of the Health
Belief Model. Transcribed interviews were analyzed for emergent topics and themes in the categories of beliefs/
understanding, personal history/narrative, consequences/limitations, management, and influences on care.
Results: Enrollment continued until theoretical saturation was obtained. Four major themes emerged from
participants’ descriptions of their experiences and perceptions: 1) changes in health status and the social impact of
chronic Lyme disease, 2) doubts about recovery and the future, 3) contrasting doctor-patient relationships, 4) and
the use of unconventional therapies to treat chronic Lyme disease.
Conclusions: Participants reported a significant decline in health status associated with chronic Lyme disease and
were often unsatisfied with care in conventional settings. Negative experiences were associated with reports of
dismissive, patronizing, and condescending attitudes. Positive experiences were associated with providers who were
reported to be attentive, optimistic, and supportive. Consultations with CAM practitioners and use of CAM therapies
were common. Actively engaged and sympathetic clinical encounters may foster greater satisfaction in healthcare
settings.
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Chronic Lyme disease (CLD) is a term that describes a
constellation of persistent symptoms in patients with or
without exposure to Borrelia burgdorferi. These symp-
toms may include fatigue, night sweats, arthralgia, myal-
gia, arrhythmias, abdominal pain, nausea, diarrhea, sleep
disturbance, cognitive dysfunction, irritability, depres-
sion, back pain, and headache [1]. There is no standard* Correspondence: ather.ali@yale.edu
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unless otherwise stated.definition of CLD; the Infectious Diseases Society of
America distinguishes between ‘post-Lyme disease syn-
drome’ or ‘late Lyme disease’ in which arthralgia and other
symptoms persist after documented B. burgdorferi infec-
tion [2], while Feder et al. [1] categorize similar syndromes
into post-Lyme disease syndrome, symptoms of unknown
cause (with our without antibodies to B. burgdorferi), and
defined illnesses unrelated to B. burgdorferi infection.
Nevertheless, patients are often are diagnosed with CLD
based on nonstandard interpretations of serology or other
testing that has little or no validity, or based on clinical
symptoms alone [2,3]. CLD is diagnosed throughout theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[1]. Individuals may make the diagnosis themselves using
lists of subjective symptoms [4,5]. Treatment protocols
can include regimens of multiple antibiotics (oral or par-
enteral), sometimes continuing for months or years [2,3].
These protocols are associated with substantial risks such
as out-of-pocket expenses, patient distress, potential harm,
as well as increasing risk of selecting for antibiotic resist-
ant bacteria [1,6].
One survey found that 2.1% of Connecticut-based pri-
mary care physicians diagnose and treat CLD, while the
majority were unsure of or did not believe in CLD [7].
The predominant infectious diseases, pediatric, and
neurology academic societies do not recognize CLD as a
distinct clinical entity, while other professional and ad-
vocacy organizations argue for a broader definition of
CLD focusing on clinical (non-serological) diagnosis
based on reported symptomology [3,8]. Patient percep-
tions of lack of sympathy and alienation from main-
stream medical institutions led to the growth of
advocacy groups supporting long-term antibiotic treat-
ment, as well as fostering ‘us vs. them’ sentiments in the
advocacy groups [8].
Qualitative methods are well suited to generate rich
data about phenomena in their context and can help de-
velop hypotheses for further research, as well as inform
the development of patient-centered interventions [9].
The purpose of this study was to gather insights about
the experiences of patients identifying themselves as
having CLD in the healthcare system using the dimen-
sions of the Health Belief Model where perceived sever-
ity, susceptibility, benefits, and barriers; as well as cues
to action, and self-efficacy are involved in influencing
health behavior choices [10]. We also aimed to gain in-
sights into therapeutic and healthcare provider choices
to better understand their illness representations, that is,
their beliefs and expectations about an illness [11,12].
Methods
Study design and sample
This was a qualitative, descriptive study in which face-
to-face in-depth interviews were conducted with patients
who were diagnosed with or self-identify as having CLD.
Purposive sampling [13] was used to recruit participants
from Connecticut-based patient-oriented Lyme disease
email lists and the website, craigslist.org. Recruitment
announcements solicited participants with CLD (diag-
nosed by a clinician or by self-diagnosis) and were will-
ing to complete an in-person interview. Participants
were not known to the investigators prior the study.
Enrollment continued until theoretical saturation was
obtained; i.e., the point at which no new concepts
emerged in a category, and in which categories were well
characterized and differentiated [9]. Demographic dataincluded sex, age, race/ethnicity (NIH criteria), years of
education, religious preference, marital status, number
of children/dependents, employment, and health insur-
ance status. Subjects were told that the aim of the study
was to gain insights into the experiences of patients with
CLD and that this information will be used to develop
interventions to improve patient care and satisfaction.
Ethics statement
The study was approved by the Human Investigation
Committee (HIC) at the Yale School of Medicine and
was compliant with HIPAA regulations.
Strategy of inquiry
An interview guide was created based on the Health
Belief Model [10] dimensions of perceived susceptibility,
severity, benefits, and barriers, as well as mediating fac-
tors such as cues to action and self-efficacy (see Table 1).
The goals of the interview were not only to gather infor-
mation about what choices were made, but to gain and
understanding of the decision-making process of pa-
tients with CLD. We were also interested in assessing
the rationale of provider and therapeutic choice, and
specific factors patients felt were important in their
decision-making processes.
Interviews were face-to-face, semi-structured and fo-
cused on the perceptions and experiences of patients, in-
cluding health beliefs, diagnostic methods, therapeutic
regimens, and perceived efficacy, using the dimensions
of the Health Belief Model [10]. Prior to each interview,
written informed consent was obtained and participants
rated their likelihood of recovery on a visual analog scale
and sense of overall well-being.
Interviews took place either at Yale University (New
Haven, CT) or at participants’ place of residence, lasted
between 60–90 min, and were conducted by two investi-
gators (AA; CAM-trained research scientist and a medical
student, both male). Interviews were recorded digitally
and transcribed by a HIPAA-compliant service (Tran-
scription Plus LLC, Bristol, CT).
Data analysis
Interviews were conducted with twelve participants; one
additional interview was conducted to corroborate find-
ings and assess saturation. Using a hermeneutic, phe-
nomenological methodology, the focus of inquiry was
placed on the patients’ lived experience with chronic
Lyme disease [14]. Transcripts were analyzed using
standard methods of content analysis [9,13]. After com-
pleting the first three interviews, transcripts were read
by the multidisciplinary investigative team for an overall
understanding to identify emergent themes. After subse-
quent interviews, and during the iterative process of
reviewing each transcript as it is collected, the list of
Table 1 Interview guide
Health belief model construct/mediating factors Question(s)
Perceived Susceptibility How would you describe your health prior to CLD?
Is there anything that you could have done differently to avoid getting CLD?
Is there anything that people can do to avoid getting CLD?
Perceived Severity How did you feel when you were diagnosed with (or discovered that you had) CLD?
How has CLD affected your life?
What does having CLD mean to you?
Perceived Benefits What treatments have you had for CLD?
How have these treatments affected you?
Perceived Barriers Have there been any obstacles that you have encountered in getting treatment for CLD?
What needs to be done to restore you to optimum health?
Do you anticipate that you’ll fully recover from CLD?
What have the doctors that have least helped your CLD not done for you?
Cues to Action What kinds of support (community, family, friends, health care providers, CLD support groups,
internet newsgroups, CLD activism groups, etc.) have you had during your CLD?
How have these support systems affected your CLD?
What motivates you in your struggle with CLD?
Self Efficacy What can doctors do to more effectively care for patients with CLD?
What can the community do to best support people with CLD?
CLD Diagnosis and Healthcare System Why does CLD best fit your symptoms?
Have you ever doubted that you have CLD?
How do you think conventional health care providers view CLD patients?
How do you think LLMDs view CLD patients?
What have the doctors that have helped your CLD the most done for you?
CLD = Chronic Lyme disease.
LLMD = Lyme literate medical doctors.
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to specific statements in each transcript, in five categor-
ies: 1) beliefs/understanding, 2) personal history/narra-
tive, 3) consequences/limitations, 4) management, and
5) influences on care. Themes were then condensed
from these categories and codes. Data from all of the
transcripts was coded using ATLAS.ti 6.1 (ATLAS.ti
Scientific Software Development GmbH, Berlin) by one
investigator (AA). Participants were not involved in the
data analysis and interpretation.
Results
Participants
All participants were White with a mean age of 41 years
(range 21–69). Seven participants were college gradu-
ates, and eleven participants had health insurance. Of
the eleven insured, CLD treatments were partially or
fully covered for eight participants (see Table 2).
Sense of well-being and likelihood of recovery
Prior to each interview, participants completed the
Arizona Integrative Outcomes Scale [15], assessing a
global sense of spiritual, social, mental, emotional, andphysical well-being, anchored by the opposing statements,
“worst you have ever been (0)” and “best you have ever
been (100)” [15] on a 10-cm visual analog scale. Mean
scores were 64 mm (range 42–87) for the 24-hour assess-
ment, and 56 mm (range 27–75) for the previous month.
Participants were also asked about their likelihood of re-
covery from CLD using a 10-cm visual analog scale
anchored by “will never recover (0)” to “will recover com-
pletely (100).” Mean scores were 31 (range 0–91).
Themes
We discussed with each participant their perceptions of
susceptibility to CLD, severity of symptoms, benefits of
treatment, and barriers to treatment and recovery using
the dimensions of the Health Belief Model [10]. We also
queried cues to action and self-efficacy in terms of exter-
nal support and motivation, as well as questions about
the diagnostic label of CLD and experiences in the
healthcare system in terms of physician interaction and
financial aspects (See Table 1).
Four major themes emerged from participants’ de-
scriptions of their experiences and perceptions. Patients
discussed: 1) Changes in health status and social impact of
Table 2 Demographic and social characteristics of participants
Participant Age Gender Marital
status















1 55 F Married Disability Provider + Self Insured Partial 57 45 13
2 51 M Married Full-time Provider Insured Partial 65 75 51
3 25 F Married Unemployed Provider Uninsured - 62 53 73
4 53 F Single Part-time Self Insured No 69 71 77
5 23 F Married Full-time Provider Insured No 42 23 27
6 21 F Single Full-time Provider Insured No 63 59 51
7 49 M Single Unemployed Provider Insured Partial 82 64 65
8 45 F Single Part-time Self Insured Full 44 56 67
9 47 F Civil Union Full-time Provider + Self Insured Partial 73 65 91
10 31 M Separated Unemployed Provider + Self Insured Partial 38 27 10
11 28 F Single Full-time Provider + Self Insured Partial 87 75 85
12 69 F Single Full-time Provider + Self Insured Full 80 61 0
*The Arizona Integrative Outcomes scale assesses a global sense of spiritual, social, mental, emotional, and physical wellbeing and is anchored by the statements
0 = “worst you have ever been” and 100 = “best you have ever been” [15].
**100 mm Visual Analog Scale anchored by the statements 0 = “will never recover” and 100 = “will recover completely”.
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future, 3) Contrasting doctor-patient relationships, and 4)
Unconventional therapies to treat chronic Lyme disease.
Theme 1: Changes in health status and social impact of
chronic Lyme disease
Eleven of the twelve participants noted that they were
highly functional in their daily lives prior to CLD and
described themselves as “athletic,” “healthy,” “perfect,”
“never sick before,” and “energetic.” All expressed sub-
stantial degradations in their quality of life after acquir-
ing CLD. One expressed frustration with the changes to
her daily routine:
“I was in excellent health before …and that’s what
really upsets me the most is the Lyme has taken away
my job that I love, making me not be able to work
and taken away my activities.” (Participant #1)
Nine participants discussed how CLD symptoms ad-
versely affected their daily activities, while nine participants
reported professional limitations, including prolonged ab-
sences from work or school or the need to enroll in a dis-
ability program. Eight participants noted social limitations,
including feeling isolated, not being understood, or others
not believing that they were ill. One participant noted that
fatigue associated with CLD resulted in social isolation:
“ I don’t feel like getting myself all riled up and
dressed up to go out on a social occasion. I’d rather
just sit back and be at home… I certainly have noticed
that I’ve become a different person since having Lyme
disease.” (Participant #8)Eight participants noted out-of-pocket financial costs as-
sociated with CLD treatment; many spent thousands to
tens of thousands of dollars on care. One participant dis-
cussed his costs in the context of insurance deductibles:
“Even though insurance pays for this… I have already
reached my out-of-pocket max and it’s August. I met it
last month and that’s $2500. That doesn’t include other
prescriptions or co-pays for August visits. That’s just
procedures like an MRI and this whole–everything to
do with this–the treatment and the inserting the [PICC]
line, and the weekly nurses.” (Participant #11)
Theme 2: Doubts about recovery and the future
Six participants were unsure about whether they would
ever fully recover from CLD, while three participants felt
that they would fully recover at some point in the future.
One participant stated that she was currently recovering
from CLD. Perceived likelihood of recovery was generally
related to beliefs surrounding the pathogenesis of CLD.
One participant noted:
“I’ve heard that you never fully recover–that it goes
into remission, so I’m not really sure if I do but I hope
maybe I will be able to.” (Participant #5)
One person expressed dismay upon seeing the extent
of disability in support group participants.
“I went to the first Lyme support group meeting;
there were people there with canes, people in
wheelchairs and I said, ‘No way…not me.’ I was like, ‘I
can’t do that, I can’t be that.’” (Participant #2)
Table 3 Reported use of complementary and alternative
(CAM) therapies


















Unconventional laboratory testing Heavy metal serum levels
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six participants were fearful that they might die from
CLD, while two discussed CLD-related suicidal thoughts.
One participant noted that her symptoms were so debili-
tating that her will to live was broken:
“I got really, really depressed and I didn’t want to live…I
ripped my PICC line out of my arm. I said, ‘I’m going to
die a slow death.’ I was begging [my boyfriend] to
smother me with a pillow.” (Participant #10)
Theme 3: Contrasting doctor-patient relationships
All participants reported strong feelings about what con-
stituted high quality care and characteristics of physi-
cians that have been most helpful in treating CLD. Two
divergent types of doctor-patient relationships emerged;
physicians were characterized as either exceptionally
supportive, or uncaring and dismissive.
Five participants characterized helpful doctors as at-
tentive and good listeners. Other attributes describing
helpful doctors included willingness to acknowledge pa-
tient concerns, open-mindedness, being supportive, opti-
mism, and a holistic approach. One participant described
a helpful physician as:
“They treat you like, like you’re someone in pain and
you’re someone that’s worthy of getting better and
getting treatment and that’s huge, ‘cause you don’t get
that from a lot of people.” (Participant #3)
Eleven participants discussed negative experiences with
clinicians. Nine participants described some clinicians as
dismissive of the diagnosis of CLD or the severity of their
symptoms. Six participants described the ‘unhelpful doc-
tors’ as condescending or patronizing. One participant felt
that her doctor was unsupportive of her concerns regard-
ing CLD as a cause of her symptoms:
“Walking in the door, he knew more than we did.
Before asking us any questions at all, I felt he’d
already made his mind up…When I asked, ‘Well what
about Lyme?’- he never tested…never asked any
questions. ‘It can’t be,’ [he said]. … It’s like, ‘Well who
are we? We have no control over our lives? We’re
stupid? We don’t know what’s going on that you
wouldn’t even consider this?’” (Participant #4)
Another participant was frustrated with her primary
care physician for not accepting her CLD status and
sought out other providers.
“I couldn’t continue to see someone who didn’t
believe I have a disease that I know I have. You know,
it’s a chronic disease and I would see him every yearfor my annual exam and he didn’t believe me.”
(Participant #9)Theme 4: Unconventional therapies to treat chronic Lyme
disease
As most participants described some negative encoun-
ters with mainstream healthcare providers and ongoing
symptomology, many sought out providers that sup-
ported prolonged antibiotic regimens (‘Lyme Literate
Medical Doctors - LLMD’ [8]) or complementary and al-
ternative medicine (CAM) therapies and providers.
All participants reported receiving multiple antibiotic
regimens (oral and/or intravenous) lasting months or
years, and all participants reported symptomatic relief
while using the antibiotics. Despite reporting relief from
conventional treatments (antibiotics) used for durations
beyond standard guidelines [2], eleven of our twelve par-
ticipants reported utilizing one or more types of CAM
therapies and providers to treat CLD. Nine participants
visited a naturopathic doctor (ND), while one participant
reported consulting a chiropractor (DC). Reported CAM
therapies are listed in Table 3.
A number of participants visited CAM providers on
referral from or in collaboration with their LLMDs [8]
to address side effects of antibiotics, to treat other symp-
toms, to provide a holistic approach, or to consult a
sympathetic clinician. One participant described her
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garding unconventional treatments:
“I went to this Naturopath and she did some
acupuncture and Reiki and I did feel this just amazing
wave go through my legs and she felt it too… I said, ‘I
feel it’s like this energy just shooting through,’ and she
put this needle in my ear and I felt it go all the way
down and out through my legs…like it released some
blockage or something…I never put much credibility to
that, so it gave me a new perspective.” (Participant #2)
Other participants were drawn to a holistic approach
from CAM providers. This 21-year old participant felt
that CLD prematurely aged her, and that the CAM pro-
vider addressed this concern:
“He’s not just attacking the Lyme; he has to get our
toxicity levels down before he even starts that. Right
now I have the toxicity level of a healthy 65 year old.
So he goes by steps, but he understands the whole
aspect of Lyme disease, not just that you need to
throw antibiotics at people…because otherwise it’s not
going to do anything. So, just like he goes in steps and
because it’s slow you don’t ‘hurx’ (Jarisch-Herxheimer
reaction) as bad.” (Participant #6)
Discussion
Our participants reported substantial limitations in their
daily lives and a decline in health status attributed to
CLD. Some believed that they would never recover and
may possibly die from CLD. Participants had polarized
experiences in the healthcare system: negative experi-
ences were associated with providers who were reported
to be dismissive, patronizing, or condescending, while
positive experiences were associated with providers re-
ported to be optimistic, attentive, and supportive. Con-
sultations with CAM practitioners and use of CAM
therapies were common.
Our cohort included participants who were diagnosed
with or self-identify as having CLD irrespective of
whether they had objective evidence of previous borre-
liosis. Because our study aimed to better understand and
describe individual and collective experiences and ideas
(e.g., the perception of a disease), strict enrollment cri-
teria utilizing serology would not be helpful. Therefore,
the only criterion for enrollment was that a person iden-
tified as a CLD patient; the etiology and classification of
their symptoms were not relevant.
Reported cases of Lyme disease to the Centers for
Disease Control and Prevention (meeting surveillance
criteria) are most common in the Northeastern United
States among children aged 5–9, and adults aged 55–59,
with male predominance (53%). Most reported cases(94%) occur in patients identified as White [16]. Our
study focused on adults; 75% of our cohort were female,
all were White.
Most participants reported general health and wellness
prior to CLD. In previous literature, health-related qual-
ity of life among CLD patients has been reported to be
similar to patients with congestive heart failure and type
2 diabetes [17]. Our participants also had a mean score
of 56 on the Arizona Integrative Outcomes Scale (AIOS)
for the month prior to their interview, indicating a com-
promised sense of well-being. Of note, Bell et al. re-
ported similar mean AIOS scores of 51 for individuals
who qualified as “psychologically distressed” on the Glo-
bal Severity Index (a standard measure of psychological
health) [15].
It is possible that this psychological distress associated
with severe symptomology, coupled with a lack of clear
disease course and uncertainty about recovery led some
to fear dying from CLD, despite CDC data indicating
that Lyme disease rarely causes death [18]. Previous
studies have found an association between CLD and
negative affect [19], and mixed results regarding an asso-
ciation with anxiety and/or depression [19,20].
Our findings also provide insight into the dimensions
of Leventhal’s illness representations of identity, cause,
timeline, control/cure, and consequences [11,12]. Our
patients strongly identified with the label of CLD, with
many expressing relief to have a diagnosis to identify
with their symptoms. Furthermore, attributing symp-
toms to active borreliosis, whether or not objective test-
ing supported this diagnosis, was empowering in the
sense that treatments (prolonged antibiotic courses and
CAM therapies) can be directed towards the bacteria to
control and possibly cure the condition. In our sample,
the timeline was necessarily chronic (and often cyclical),
as we selected patients identifying with CLD and not ne-
cessarily having a history of acute Lyme disease. The
consequences of CLD in our cohort were remarkable,
impacting social relationships, and activities of daily liv-
ing, as well as perceptions of mortality and debility.
Some literature has classified CLD as ‘medically unex-
plained symptoms’ [1]. Symptomatically, CLD can re-
semble other such conditions including chronic fatigue
syndrome and fibromyalgia [21], as well as neurologic
conditions such as amyotrophic lateral sclerosis [22] or
multiple sclerosis [23]. The lack of clear pathophysiology
often results in extensive diagnostic workups and signifi-
cant iatrogenic complications [24]. Like many chronic
pain conditions, depressive and anxiety disorders are
prevalent and can be overlooked [19]. At least 13% of
outpatient visits can be attributed to medically unex-
plained symptoms [24].
In one study, a majority of primary care physicians de-
scribed their attitudes towards patients as negative and
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discordance between patient and physician treatment
goals [26]. Previous studies of other medically unexplained
conditions note that patients often identify as ‘medical or-
phans’ without a medical specialty home to seek treat-
ment. Further, their symptoms are frequently labeled
psychosomatic, and their stories described as ‘chaos narra-
tives’ lacking a defined illness trajectory with uncertainty
about persistence or improvement of symptoms [27].
Our participants reported similar experiences. Congru-
ent with our findings, Nunes et al. [28] also found pa-
tient concerns regarding about the illness severity to
predominate over concerns about symptomatic relief in
a qualitative study of patients with medically unex-
plained symptoms. In a study of persons with fibromyal-
gia, LaChapelle et al. found that patients reported mixed
feelings about support groups; some valued the ‘safe
haven’ aspect as an encouraging environment with peers,
while other patients reported discouragement from
others, perceived to be “building their whole life around
the disease” [29].
As is true of many health conditions that are poorly
understood and often resistant to conventional treat-
ments, medically unexplained conditions often compels
those afflicted to seek CAM therapies and providers
[30,31] including over-the-counter products, mind-body
practices, dietary modifications, acupuncture, and chiro-
practic [32].
The majority (11/12) of our participants used one or
more forms of CAM, and most consulted a CAM pro-
vider. To the best of our knowledge, this is the first
study to report frequent CAM use among CLD patients.
The high prevalence of CAM was unexpected given that
recruitment occurred in general (not CAM-oriented)
email lists. It is possible that patients were more open to
discussing CAM in a study led by a CAM-trained inves-
tigator (AA), whereas patients often feel reluctant to dis-
cuss CAM use with conventional providers [33].
It is possible that CLD patients are attracted to uncon-
ventional providers – those providing extensive antibiotic
regimens beyond current guidelines (‘Lyme-literate med-
ical doctors’) and/or CAM providers due to the lack of
symptomatic relief, as well as a perceived lack of sympathy
to the diagnosis of CLD in more conventional settings.
Our participants reported greater satisfaction with pro-
viders described as being ‘open minded’ and supported
the use of CAM therapies, while expressing frustration
with doctors perceived as dismissive after serology ruled
out Lyme disease. The extensive financial expenditures re-
ported may be reflective of a desire for therapeutic options
beyond those conventionally available [34].
Some reported CAM therapies may be of questionable
value (i.e., the Rife Machine purporting to detect ‘vibra-
tions’ in the body to aid in diagnosis and treatment),while others may be directly harmful. For example,
thujone-containing extracts of Artemesia absinthium
(wormwood) can cause seizures, rhabdomyolysis, and
acute renal failure [35], while the use of oral colloidal sil-
ver is associated with neurological deficits, diffuse silver
deposition in visceral organs, and renal damage. Never-
theless, our participants did not report any adverse ef-
fects from CAM therapies.
This study has several limitations. It was restricted to
one geographic area where Lyme disease is endemic
(Connecticut, USA), and social awareness of CLD is
prevalent. Though our sample was small, theoretical sat-
uration was reached. Furthermore, our participants were
ethnically homogenous and computer literate, and a
priori, identified with CLD. Our results may therefore
not apply to more diverse groups of CLD patients and
those in other geographic locations.
Conclusions
This study provides insights into the health beliefs and
lived experiences of CLD patients. Most participants ex-
perienced a considerable decline in their health status at-
tributed to CLD and expressed concerns about long-
term debilitation. Participants reported polarized experi-
ences in healthcare settings and sought out CAM pro-
viders and therapies. Many participants sought out and
were treated by highly invasive (long-term antibiotic reg-
imens), at strong contrast to other chronic conditions
where less-invasive therapies are desired [36].
Patient-centered outcomes research approaches [37],
emphasizing research propelled by patient interest, may
be most appropriate for medically unexplained conditions
such as CLD. Actively engaged and sympathetic clinical
encounters may foster greater satisfaction in healthcare
settings, where patient concerns are fully acknowledged
and addressed. Further study of the perceptions and de-
sires of CLD patients as well as the use, efficacy, and safety
of unconventional therapies for CLD are warranted.
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